This study compared the effectiveness and safety of two treatment algorithms for insulin detemir initiation and titration: active titration algorithm (performed by investigator weekly) versus usual titration algorithm (performed by study subjects weekly) in patients with type 2 diabetes poorly controlled by OADs.
This is a 24-week, prospective, open-label, randomized, parallel-group study conducted in approximately 200 patients with type 2 diabetes in the Taiwan. The effectiveness of insulin detemir will be assessed at baseline and at 12 and 24 weeks after initiation of study prescription. The safety will be followed during the 24-week study period. Inclusion criteria: Patients must meet all of the following criteria: 1. Men and women with type 2 diabetes. 2. 20 years of age. 3. Patients who have received stable doses of any OADs for at least 10 weeks prior to the screening visit. 4. Patients with inadequate glycemic control (HbA1C \>=7% and \< 11%). 5. Patients who are willing and able to cooperate with study and give signed informed consent. After enrollment, eligible patients will be randomized in a 1:1 ratio to one of the following titration algorithms: * Active titration algorithm: contact with investigator by telephone weekly. * Usual titration algorithm: contact with investigator only at routine study visit.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
181
Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(\<110mg/dl).
All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG\>=110mg/dL, and by 4 IU/day if the FPG\>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG \< 70 mg/dL.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital Hsinchu branch
Hsinchu, Taiwan
Mackay Memorial Hospital
Taipei, Taiwan
Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital Taitung branch
Taitung, Taiwan
To compare the change in HbA1c between two study groups at Week 24.
compare the change in HbA1c between two study groups after 24 weeks treatment.
Time frame: 24 weeks
To compare the change in HbA1C between two study groups at Week 12.
compare the change in HbA1C between two study groups after 12 of treatment.
Time frame: 12 weeks
To compare the proportion of patients achieving HbA1C <7% at Week 24
compare the proportion of patients achieving HbA1C \<7% after 24 weeks treatment
Time frame: 24 weeks
To compare the changes in fasting plasma glucose (FPG) at Week 12 and 24.
compare the changes in fasting plasma glucose (FPG) after 12 and 24 treatment.
Time frame: 24 weeks
To compare the change in body weight at each visit
compare the change in body weight at each visit
Time frame: 24 weeks
To evaluate the incidence of adverse events.
evaluate the incidence of adverse events including hypoglycemia and any other adverse event.
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.